Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Novartis    NOT   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

NOVARTIS : completes merger with Alcon

share with twitter share with LinkedIn share with facebook
share via e-mail
04/08/2011 | 04:05pm CEST

Novartis International AG / Novartis completes merger with Alcon . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

  • Novartis shares required in transaction total 165 million shares instead of 215 shares million following purchase of Alcon shares in open market
    • The 108 million new shares in combination with an additional 57 million shares held in treasury used to fund part of the merger consideration
  • Merger of Alcon into Novartis completed following entry in commercial registry


Basel, April 8, 2011 - Novartis announced today that it completed the merger of Alcon, Inc. (Alcon; NYSE: ACL) into Novartis. The completion of the merger follows the Novartis shareholders' approval of the merger, as well as the proposed capital increase at the company's Extraordinary Shareholder Meeting today and the subsequent entry of the merger into the commercial registry.


The number of Novartis shares required in connection with the merger are 165 million shares instead of the initially expected 215 million shares. The amount of shares required for the merger was reduced through the purchase of 16.1 million Alcon shares in the open market since the announcement of the merger agreement in December 2010. 


The 165 million shares are composed of 108 million newly issued shares from the authorized capital increase approved by the Novartis Board of Directors today and 57 million shares already held as treasury shares. Under the terms of the agreement, Alcon shareholders will receive 2.9228 Novartis shares (which includes the dividend adjustment) and USD 8.20 in cash for each share of Alcon, for a total consideration of USD 168 per share.


Novartis has appointed Mellon Investor Services LLC (operating with the service name BNY Mellon Shareowner Services) as agent for the payment of merger consideration. Alcon shareholders with questions regarding the payment of merger consideration should contact BNY Mellon Shareowner Services at +1 (201) 680-6579.


A full update on expected synergies, one-time costs and progress of integration process resulting from the merger will be provided with the Novartis quarterly earnings update on April 19, 2011.


These materials contain forward-looking statements that can be identified by terminology such as "will," "to be issued," "will continue," "expected," "committed," "would," or similar expressions, or by express or implied discussions regarding potential future sales or earnings of the Novartis Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the Novartis Group, or any of its divisions will achieve any particular financial results. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including additional analyses of existing clinical data or unexpected new clinical data; the Group's ability to obtain or maintain patent or other proprietary intellectual property protection; disruptions from the integration of Alcon making it more difficult to maintain business and operational relationships, and relationships with key employees; unexpected product manufacturing issues; uncertainties regarding actual or potential legal proceedings, including, among others, litigation seeking to prevent the merger from taking place, product liability litigation, litigation regarding sales and marketing practices, government investigations and intellectual property disputes; competition in general; government, industry, and general public pricing and other political pressures; uncertainties regarding the after-effects of the recent global financial and economic crisis; uncertainties regarding future global exchange rates and uncertainties regarding future demand for our products; uncertainties involved in the development of new eye care products; the impact that the foregoing factors could have on the values attributed to the Group's assets and liabilities as recorded in the Group's consolidated balance sheet; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing the information in these materials as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


About Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 119,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com:


# # #



Novartis Media Relations


Central media line : +41 61 324 2200  
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
[email protected]:
mailto:[email protected]


e-mail: [email protected]:
mailto:[email protected]


Novartis Investor Relations


Central phone: +41 61 324 7944    
Susanne Schaffert +41 61 324 7944 North America:  
Pierre-Michel Bringer +41 61 324 1065 Richard Jarvis +1 212 830 2433
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: [email protected]:
mailto:[email protected]
e-mail: [email protected]:
mailto:[email protected]
Media release (PDF):

--- End of Message ---

Novartis International AG
Postfach Basel

WKN: 904278;ISIN: CH0012005267;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Novartis International AG via Thomson Reuters ONE

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
05/26NOVARTIS : European Commission approves Sandoz`s Zessly to treat gastroenterolog..
05/26GLOBAL ACTIVE PHARMACEUTICAL INGREDI : Pfizer, Inc., Novartis International AG, ..
05/25NOVARTIS : Patent Issued for Surgical Guidance and Planning Software for Astigma..
05/25NOVARTIS : Patent Issued for Ophthalmic Illumination Systems, Devices, and Metho..
05/25NOVARTIS : Patent Issued for Ophthalmic Lens Having an Extended Depth of Focus (..
05/25NOVARTIS : announces FDA approval of Gilenya® as the first disease-modifying the..
05/25FINDINGS IN THE AREA OF ONCOLOGY REP : a platform of basket trials)
05/25NOVARTIS` : Sandoz scores EU approval for Remicade biosimilar
05/25NOVARTIS : Sandoz receives European Commission approval for Zessly in gastroente..
05/25JOHNSON & JOHNSON : EU nod for Sandoz Remicade biosimilar Zessly
More news
Financials ($)
Sales 2018 52 599 M
EBIT 2018 13 274 M
Net income 2018 9 218 M
Debt 2018 13 550 M
Yield 2018 3,89%
P/E ratio 2018 15,81
P/E ratio 2019 18,75
EV / Sales 2018 3,95x
EV / Sales 2019 3,80x
Capitalization 194 B
Duration : Period :
Novartis Technical Analysis Chart | NOT | CH0012005267 | 4-Traders
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 90,6 $
Spread / Average Target 19%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-7.46%194 397
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708